High CXCL10/IP-10 levels are a hallmark in the clinical evolution of the HIV infection

被引:29
|
作者
Maria Valverde-Villegas, Jacqueline [1 ,2 ]
de Medeiros, Rubia Marilia [1 ,2 ]
Ellwanger, Joel Henrique [1 ]
Santos, Breno Riegel [3 ]
de Melo, Marineide Goncalves [3 ]
de Matos Almeida, Sabrina Esteves [2 ,4 ,5 ]
Bogo Chies, Jose Artur [1 ]
机构
[1] Univ Fed Rio Grande do Sul, Dept Genet, Lab Imunobiol & Imunogenet, Av Bento Goncalves 9500,Campus Vale,POB 15053, BR-91501970 Porto Alegre, RS, Brazil
[2] FEPPS, Porto Alegre, RS, Brazil
[3] Grp Hosp Nossa Senhora da Conceicao, Serv Infectol, Porto Alegre, RS, Brazil
[4] Univ Feevale FEEVALE, Inst Ciencias Saude, Novo Hamburgo, RS, Brazil
[5] Univ Fed Rio Grande do Sul, Dept Genet, Porto Alegre, RS, Brazil
关键词
CXCL10; CCL20; AIDS progression; HAART; Biomarkers; PLASMA CYTOKINE LEVELS; ANTIRETROVIRAL THERAPY; T-CELLS; IMMUNE ACTIVATION; TYPE-1; INFECTION; CHEMOKINE LEVELS; EXPRESSION; AGE; TRANSMISSION; INFLAMMATION;
D O I
10.1016/j.meegid.2017.11.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to investigate the modulation of plasma CXCL10, CCL20, CCL22, CCL2, CCL17 and CCL24 levels in HIV-positive patients grouped according to extreme phenotypes of progression to AIDS, and at different stages of HIV infection. HIV-positive individuals with extreme phenotypes of AIDS progression (n = 58) at different clinical stages (chronic individuals, both pre-HAART and under-HAART) and HIV-negative controls (n = 20) were evaluated. Additionally, HIV-positive individuals that initiated HAART with> 350 CD4+ T-cells/mm3 were compared with those who initiated treatment with< 350 CD4+ T-cells/mm(3). Plasma levels of six chemokines were quantified by a Luminex assay. Higher CXCL10 levels were observed in individuals immediately before their CD4+ T-cell levels were indicative for HAART (pre-HAART), independently of their progressor status, i. e. slow (SPs) or rapid progressors (RPs). SPs pre-HAART showed higher CXCL10 levels compared to elite controllers and RPs under HAART (pc = 0.009 and pc = 0.007, respectively). CXCL10 levels were higher in SPs HAART CD4 < 350 (initiated HAART with< 350 CD4+ T-cells) when compared with SPs HAART CD4 > 350 (initiated HAART with> 350 CD4+ T-cells) (1096 vs. 360.33 pg/mL, p = 0.0101). Normalisation of CXCL10 levels seems to depend on the CD4+ T-cell nadir at HAART initiation. CCL20 levels were higher in chronic SPs, SPs pre-HAART, SPs HAART and RPs HAART compared with the HIVnegative controls, indicating persistent CCL20 expression. In conclusion, our results indicate that CXCL10 levels are a hallmark in the clinical evolution of HIV infection. However, our results must be verified in a study evaluating a larger number of AIDS progressors.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 50 条
  • [1] EVIDENCE FOR CXCL10 (IP-10) ANTAGONISM IN CHRONIC HCV INFECTION
    Mallet, V.
    Casrouge, A.
    Vallet-Pichard, A.
    Ahloulay, M.
    Pol, S.
    Albert, M.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S122 - S122
  • [2] Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease
    Romagnani, P
    Rotondi, M
    Lazzeri, E
    Lasagni, L
    Francalanci, M
    Buonamano, A
    Milani, S
    Vitti, P
    Chiovato, L
    Tonacchera, M
    Bellastella, A
    Serio, M
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (01): : 195 - 206
  • [3] Cerebrospinal fluid interferon-γ-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection
    Cinque, P
    Bestetti, A
    Marenzi, R
    Sala, S
    Gisslen, M
    Hagberg, L
    Price, RW
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2005, 168 (1-2) : 154 - 163
  • [4] CXCL10/IP-10 Is a Biomarker and Mediator for Kawasaki Disease
    Ko, Tai-Ming
    Kuo, Ho-Chang
    Chang, Jeng-Sheng
    Chen, Shih-Ping
    Liu, Yi-Min
    Chen, Hui-Wen
    Tsai, Fuu-Jen
    Lee, Yi-Ching
    Chen, Chien-Hsiun
    Wu, Jer-Yuarn
    Chen, Yuan-Tsong
    [J]. CIRCULATION RESEARCH, 2015, 116 (05) : 876 - 883
  • [5] An IP-10 (CXCL10)-Derived Peptide Inhibits Angiogenesis
    Yates-Binder, Cecelia C.
    Rodgers, Margaret
    Jaynes, Jesse
    Wells, Alan
    Bodnar, Richard J.
    Turner, Timothy
    [J]. PLOS ONE, 2012, 7 (07):
  • [6] Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10
    Tager, AM
    Kradin, RL
    LaCamera, P
    Bercury, SD
    Campanella, GSV
    Leary, CP
    Polosukhin, V
    Zhao, LH
    Sakamoto, H
    Blackwell, TS
    Luster, AD
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2004, 31 (04) : 395 - 404
  • [7] Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease
    Rocha, Natalia Pessoa
    Scalzo, Paula Luciana
    Barbosa, Izabela Guimaraes
    Souza, Mariana Soares
    Morato, Isabela Boechat
    Marciano Vieira, Erica Leandro
    Christo, Paulo Pereira
    Teixeira, Antonio Lucio
    Reis, Helton Jose
    [J]. PARKINSONS DISEASE, 2014, 2014
  • [8] High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure
    Rotondi, M
    Rosati, A
    Buonamano, A
    Lasagni, L
    Lazzeri, E
    Pradella, F
    Fossombroni, V
    Cirami, C
    Liotta, F
    La Villa, G
    Serio, M
    Bertoni, E
    Salvadori, M
    Romagnani, P
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (09) : 1466 - 1474
  • [9] Induction of IP-10 (CXCL10) in astrocytes following Japanese encephalitis
    Bhowmick, Sourojit
    Duseja, Rachna
    Das, Sulagna
    Appaiahgiri, Mohan Babu
    Vrati, Sudhanshu
    Basu, Anirban
    [J]. NEUROSCIENCE LETTERS, 2007, 414 (01) : 45 - 50
  • [10] CXCL10/IP-10, an early biomarker for late sequelae in DRESS?
    Bellon, T.
    Kardaun, S. H.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (05) : 804 - 805